Mitochondrial disease is a commonly occurring inherited condition, incidence 1/5000, which can affect every organ system and thus exhibits a broad range of clinical phenotypes. The most common are neurological and neuromuscular dysfunction that manifest as neurodegeneration, seizures, ataxia, chronic progressive external opthalmoplegia (CPEO), and hypotonia. Childhood-onset mitochondrial disease most often results from mutations in the nuclear genome; however, the majority of cases remain without a molecular diagnosis and no effective treatments thus underscoring the critical need to identify the genetic aberrations driving these disorders. We propose a personalized functional genomics approach combining genome-wide sequencing, transcriptomics, metabolomics and mitochondrial functional profiling in cells to identify validated novel mitochondrial disease genes and variants. We will leverage a multi-omic strategy for identifying the pathogenic genes and elucidating pathomechanisms: 1. Genome-wide sequencing of patients coupled with transcriptomics and metabolomics 2. Cell-based functional studies of genes and pathways identified in patients. Through our international network of collaborators we have collected patients with clinically confirmed primary mitochondrial encephalopathy who do not have a molecular diagnosis. For patients who have already had WES/WGS but no molecular diagnosis we will re-interpret these data and leverage our ability to interpret beyond ABMGG guidelines for diagnosis. Additionally, we have a parallel effort to identify disease genes through datamining the clinical exome database at Baylor Genetics diagnostic laboratory wherein genes that are known to be essential for mitochondrial function but are not yet demonstrated as disease causing are analyzed for mutations in patients. Gene causality will be determined through a series of cell-based disease modeling experiments of mitochondrial functional profiling that include strategies of gene knock down, high-throughput mutagenesis knock-in, and cDNA complementation studies. We will utilize this technology to test the functionality of variants of uncertain significance identified in our sequencing efforts as well as those obtained through collaborators, diagnostic laboratories, and the public domain. This work will generate an unprecedented resource of systematic profiling of cellular mitochondrial function and functionally- confirmed pathogenic molecular defects. The elucidation of these pathogenic genes and variants will immediately improve the molecular diagnostic potential for children with suspected mitochondrial disease. Moreover, by identifying the pathogenic genes for primary mitochondrial encephalopathy we will empower the scientific community focused on neurological and neurodegenerative disorders, which have a more complex etiology, by delivering genes and pathways for further study of the pathogenetic mechanisms of these global health problems.
In this proposal we will identify genetic variants causing childhood-onset mitochondrial disease through the multi-omic approach of genome-wide sequencing, transcriptomics and metabolomics combined with mitochondrial functional studies in cell-based models of disease. This work will significantly advance the diagnosis and treatment of mitochondrial disease, as well as provide new insights into the mechanisms underlying the pathology of mitochondrial disorders and commonly occurring conditions associated with mitochondrial dysfunction such as neurological and neurodegenerative disorders.
Showing the most recent 10 out of 23 publications
